Medical Condition News

RSS

Santarus, Depomed enter new commercialization agreement for GLUMETZA

Santarus, Inc. and Depomed, Inc. today announced that they have entered into a new commercialization agreement for GLUMETZA (metformin hydrochloride extended release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement that the companies entered into in July 2008.

23 Aug 2011

IsoRay Cs-131 mesh brachytherapy with da Vinci Robot for lung cancer treatment gains momentum

IsoRay, Inc. said today that a growing number of hospitals and medical treatment centers are adopting its proprietary mesh Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) for use in conjunction with the da Vinci® Surgical System to treat early stage lung cancer patients. One of the most recent adopters is Georgia's Archbold Memorial Hospital.

23 Aug 2011

Scientists identify molecular pathway that plays a key role in stress-related DNA damage

Working closely with a team of researchers from Duke University, scientists from the Florida campus of The Scripps Research Institute have helped identify a molecular pathway that plays a key role in stress-related damage to the genome, the entirety of an organism's hereditary information.

23 Aug 2011

CTI responds to EMA's Day 120 letter for pixantrone MAA

Cell Therapeutics, Inc. today announced that it has submitted its response to the Day 120 List of Outstanding Issues to the European Medicines Agency's Committee for Medicinal Products for Human Use in regards to CTI's Marketing Authorization Application for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Aug 2011

Stem cells of oral mucosa stay young, says Tel Aviv University researcher

While highly potent embryonic stem cells are often the subject of ethical and safety controversy, adult-derived stem cells have other problems. As we age, our stem cells are less pliant and less able to transform into the stem cells that science needs to find breakthrough treatments for disease.

23 Aug 2011

DMS receives NIH grant to establish Center of Biomedical Research Excellence

Under an $11-million grant from the National Institutes of Health (NIH), Dartmouth Medical School (DMS) will lead a network of northern New England institutions in recruiting, training, and supporting young quantitative biologists to teach and conduct research into the ways that genes and the environment work together to trigger and prevent disease.

23 Aug 2011

Almost all heart attack patients receive angioplasty within 90 minutes of being admitted

Almost all heart attack patients who need the emergency artery-opening procedure known as angioplasty are receiving it within 90 minutes of being admitted to the hospital, a marked improvement from five years ago when most patients waited longer for the life-saving procedure, according to a report by Yale School of Medicine researchers and their colleagues.

23 Aug 2011

New research reveals stubbornly low public awareness of bowel cancer

BRITONS have very low awareness of the signs and symptoms of bowel cancer - the third most common cancer in the UK and second largest cause of cancer deaths each year, new research shows.

23 Aug 2011

ARUP Laboratories introduces Affymetrix CytoScan HD Array

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, is pleased to introduce its newest SNP-based microarray technology, the Affymetrix CytoScan HD Array.

23 Aug 2011

AstraZeneca announces availability of BRILINTA tablets in the U.S. pharmacies

AstraZeneca today announced that BRILINTA tablets, a new oral antiplatelet therapy, is now available in pharmacies in the United States.

23 Aug 2011

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated today announced that Health Canada has approved INCIVEK tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

23 Aug 2011

MME, WNDM sign major agreement to distribute CellerateRX

Wound Management Technologies, Inc., a leader in advanced wound care solutions, today announced a major distribution deal with Marketing Media Enterprises, LLC (MME), an Orlando Florida medical products distributor serving the direct-to-consumer and military market.

23 Aug 2011

Nurse safety measures around highly toxic drugs needed

Nearly 17 percent of nurses who work in outpatient chemotherapy infusion centers reported being exposed on their skin or eyes to the toxic drugs they deliver, according to a new study from the University of Michigan Comprehensive Cancer Center.

22 Aug 2011

New report on adverse effects of vaccines

Vaccines have dramatically reduced illnesses and deaths due to infectious diseases over the past century. However, no pharmaceutical product is completely without risk and some people have experienced health problems associated with immunization.

22 Aug 2011

Risk of Parkinson's disease increases with traumatic brain injury and exposure to pesticide paraquat

Traumatic brain injury has entered the public's consciousness as the silent, signature wound brought back by many of our military warriors from Iraq and Afghanistan. But such injuries don't only happen in warfare, they happen to civilians too. Think car crashes, a slip and fall, two football players colliding helmet to helmet.

22 Aug 2011

A CRADA for prostate disease research

Genomatix Software, the Uniformed Service University of the Health Sciences (USU), and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) have entered into a Cooperative Research and Development Agreement (CRADA) to extend their collaborative endeavors in prostate disease research.

22 Aug 2011

Saffron promotes apoptosis and inhibits growth of cancerous cells

New research suggests that saffron provides a significant chemopreventive effect against liver cancer in animal models. When saffron was administered to rats with diethylnitrosamine (DEN)-induced liver cancer an inhibition of cell proliferation and stimulation of apoptosis was observed. Full findings appear in the September issue of Hepatology, a journal published by Wiley Blackwell on behalf of the American Association for the Study of Liver Diseases.

22 Aug 2011

Risk of depression in formerly depressed people

Depression is increasingly recognized as an illness that strikes repeatedly over the lifespan, creating cycles of relapse and recovery. This sobering knowledge has prompted researchers to search for markers of relapse risk in people who have recovered from depression. A new paper published in Elsevier's Biological Psychiatry suggests that when formerly depressed people experience mild states of sadness, the nature of their brains' response can predict whether or not they will become depressed again.

22 Aug 2011

No effective treatment yet for acute lung injury

Patients can essentially drown in their own fluids when trauma and infection prompt blood vessels to leak, flooding millions of air sacs in their lungs.

22 Aug 2011

Johns Hopkins establishes Center for Personalized Cancer Medicine with Commonwealth Foundation gift

A $30 million gift from the Commonwealth Foundation for Cancer Research has enabled the Johns Hopkins Kimmel Cancer Center to establish a Center for Personalized Cancer Medicine. The gift from the Richmond, VA- based foundation, will be used to support research and the development of new technologies that pinpoint the novel genetic characteristics of each patient's cancer.

22 Aug 2011